GlaxoSmithKline PLC (NYSE:GSK)

40.19
Delayed Data
As of Aug 16
 +0.23 / +0.58%
Today’s Change
36.41
Today|||52-Week Range
42.47
+5.18%
Year-to-Date
Better Buy: Eli Lilly vs. GlaxoSmithKline
7:28am / MotleyFool.com - Paid Partner Content
AnaptysBio Prepares for a Potential Gear Shift
Aug 10 / MotleyFool.com - Paid Partner Content
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Aug 14 / MotleyFool.com - Paid Partner Content
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
Aug 09 / Zacks.com - Paid Partner Content
Should Value Investors Consider GlaxoSmithKline (GSK) Stock?
Aug 13 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close39.96
Today’s open40.21
Day’s range40.15 - 40.39
Volume1,367,110
Average volume (3 months)2,409,965
Market cap$96.5B
Data as of 4:01pm ET, 08/16/2019

Growth & Valuation

Earnings growth (last year)+143.10%
Earnings growth (this year)-7.36%
Earnings growth (next 5 years)+4.00%
Revenue growth (last year)+5.72%
P/E ratio18.6
Price/Sales2.31
Price/Book17.14

Competitors

 Today’s
change
Today’s
% change
SNYSanofi+0.37+0.89%
ABBVAbbVie+1.45+2.30%
LLYEli Lilly and Co+0.29+0.26%
NVONovo Nordisk+1.37+2.72%
Data as of 6:30pm ET, 08/16/2019

Financials

Next reporting dateOctober 23, 2019
EPS forecast (this quarter)$0.78
Annual revenue (last year)$41.1B
Annual profit (last year)$4.8B
Net profit margin11.75%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Emma Walmsley
Chief Financial Officer &
Executive Director
Iain James Mackay
Corporate headquarters
Brentford, Greater London

Forecasts